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Total number of matched SBs for analysis was 138, 72 in-stent and 66 in native vessels.
Two SBs had kissing balloon dilatation and were grouped with jailed SBs. Analysis of the
entire first millimeter was possible in 58% of analyzed SBs. Mean native ostial area was
increased from 1.671.61 mm2 at baseline to 1.741.85 mm2 (p0.44) at FU. Average
in-stent ostial area was increased from 1.301.42 mm2 at baseline to 1.521.54 mm2
(p0.06) at FU. In-stent ostial area gain between baseline and FU for Cypher was
0.321.00 mm2 vs. 0.080.92 mm2 (p0.32) for Nobori. Neointimal bridging occurred
in 13 (10%) of all assessed FU SBs. Intra-observer mean difference was 0.0010.12 mm2
and inter-observer mean difference was 0.0120.23 mm2.
Conclusions: Ostial SB evaluation by 3D reconstruction of main vessel OCT acquisition
is feasible when the ostium is visible and can be performed with high intra- and
interobserver agreement. DES-jailed SBs tended to improve in ostial MLA at 12-month
FU while mean MLA in native SB ostia remained unchanged.
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Background: The DESolve Bioresorbable Scaffold (BS) is a novel PLLA-based scaffold
coated with a bioresorbable polylactide-based polymer and the drug Myolimus (3
mcg/mm of scaffold length). Myolimus, a macrocyclic lactone mTOR inhibitor, has
shown potent anti-proliferative properties in two First-in-Man (FIM) trials using Elixir’s
metallic coronary stents. We aim to present the OCT results of the FIM evaluation of this
novel BS.
Methods: 15 pts treated with a single 3.0x14 mm DESolve at 3 centers were enrolled.
Serial (baseline and 6-month follow-up) OCT was available for 10 pts. All images were
analyzed by an independent core laboratory at 0.6-mm interval. At baseline, scaffold
malapposition and scaffold structural discontinuity (qualitatively defined as  2 struts
overhanging each other in the same angular sector of the lumen, or by isolated struts
floating inside the lumen in complete misalignment with the surrounding struts) were
assessed. At follow-up, serial changes in lumen and scaffold dimensions and degree of
NIH formation on top of the struts were assessed. Frequency of covered struts and NIH
thickness on top of each strut were also examined. Scaffold and strut malapposition were
serially assessed at the cross-section and strut levels respectively.
Results: At baseline, no signs of structural discontinuity were observed at the cross-
section level inspection. Scaffold area was maintained over time with no evidence of
scaffold recoil from baseline (6.570.68 mm2) to follow-up (6.800.85 mm2, p0.344).
NIH area measured 0.710.36 mm2, with 13.165.59% obstruction of the scaffold area.
At 6 months, 2,575 struts were analyzed and 98.7% were covered with a very thin NIH
(0.120.04 mm). Scaffold malapposition was observed in only 1 cross-section of 1
scaffold. Rate of malapposed struts per scaffold varied from 2.012.75% to 0.040.12%
over time (p0.016).
Conclusions: The DESolve Scaffold exhibited maintenance of its structural integrity
upon deployment, proproviding excellent mechanical support without chronic recoil. At
6 months, it demonstrated effective NIH suppression without compromising tissue
coverage of the polymeric struts,with virtually complete resolution of acute scaffold
malapposition.
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Background: There are limited data about predictors of acute stent malapposition (ASM)
and late persistent stent malapposition (LPSM) detected by optical coherence tomography
(OCT).
Methods: A total of 252 patients (257 lesions) who underwent both post-stent and
follow-up OCT were enrolled for analysis. Malapposed struts on post-stent OCT were
identified and those struts were re-evaluated on follow-up OCT. Various clinical,
angiographic, and OCT parameters were evaluated to identify predictors of ASM and
LPSM.
Results: On post-stent OCT, 169 lesions (66%) showed ASM with malapposed strut %
of 5.3  6.5. In univariate analysis, ASM lesion was associated with calcification, B2 or
C lesion complexity, intra-coronary thrombus seen on OCT, post-balloon dissection,
sirolimus-eluting stent (SES), and long stent length (20 mm) more frequently than
No-ASM lesion. However, only calcification (odds ratio [OR]  10.9; 95% confidence
interval [CI], 1.3-92.0; p  0.029) and long stent length (20 mm; OR  2.6; 95% CI,
1.1-6.6; p 0.042) were independent predictors of ASM in multivariate analysis. Of 169
ASM lesions, 55(33%) showed LPSM and 114(67%) showed resolved-ASM on
follow-up OCT which was performed at 167  52 and 169  63 days after the index
procedure, respectively (p  0.806). In univariate analysis, LPSM lesion showed higher
frequency of SES, older patient age, higher baseline diameter stenosis %, higher
malapposed strut % on post-stent OCT, and smaller neointimal thickness on follow-up
OCT than resolved-ASM lesion. Patient age (60 years) was the only independent
predictor of LPSM in multivariate analysis (OR  3.7; 95% CI, 1.2-12.7; p  0.042).
Uncovered strut % on follow-up OCT was higher in LPSM lesion than resolved-ASM
lesion (30% vs. 10%, p0.001). However, there were no significant differences of major
adverse cardiac events between LPSM and resolved-ASM lesion during 2-year follow-up
(3.6% vs 2.6%, respectively, p  0.661).
Conclusions: In this OCT study, calcification and long stent length were the independent
predictors of ASM. The predictor of LPSM was patient age. LPSM was not associated
with increased risk of clinical events.
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Background: Both impaired vascular healing and proliferative tissue response, including
neoatherosclerosis, play a role in the pathogenesis of late stent failure, presenting either as
restenosis or stent thrombosis. We investigated the association of neoatherosclerosis and
neointimal rupture with clinical presentation in patients late after coronary stent implan-
tation by optical coherence tomography (OCT).
Methods: From 1/1/2007 to 31/1/2012, 74 patients from two institutions underwent OCT
assessment of a coronary stent implanted at least 18 months prior to examination. In 39
of the patients the studied stent was the culprit of acute coronary syndrome (ACS)
(myocardial infarction n34; unstable angina n5), in 13 patients the culprit of stable
angina (SA), whereas 22 patients had no symptoms attributed to the studied stent
(asymptomatic). Stents containing 5 frames (1mm) with 30% uncovered struts were
considered uncovered, while stents with 5% malapposed struts were considered
malapposed.
Results: Intervals since implantation were similar among the different clinical presenta-
tions [ACS: median 65 months (range 22-201), SA: 76.5 months (31-168), asymptomatic:
53.5 (21-168); p0.19]. The incidence of neoatherosclerosis within the stent (n44
stents) was higher in symptomatic than in asymptomatic patients (66.7% in ACS, 84.6%
in SA and 31.8% in the asymptomatic group [p0.01]). The incidence of neointimal
rupture was higher in the ACS group (41%) vs. SA (15.4%) and asymptomatic (4.5%;
p0.01). Thrombus was evident in 97.4% of patients with ACS vs. 23.1% SA and 9.1%
asymptomatic (p0.01). Incomplete coverage was similar between SA (22.7%) and
asymptomatic (23.1%) but more frequently in the ACS group (65.8%; p0.01), whereas
the incidence of malapposition was comparable among the three groups (ACS: 33.3%,
SA: 15.4%, asymptomatic: 22.7%; p0.39).
Conclusions: Not only impaired vascular healing, but neoatherosclerosis and neointimal
rupture as well, seem to contribute significantly in the pathogenesis of late stent failure,
being associated with symptomatic presentation late after coronary stent implantation.
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Background: Manufacturer-predicted stent expansion is based on in-vitro testing. Actual
expansion is related to stent architecture, lesion characteristics, etc. We evaluated the
relationships between these variables on coronary DES expansion via IVUS.
Methods: 1,652 IVUS frames were acquired and blindly analyzed in 56 lesions post-DES
via Volcano EagleEye Platinum 20 MHz IVUS. DES studied were Medtronic Endeavor
(n32, 666 mm) and Resolute (n12, 266 mm), and Abbott Xience V (n12, 215 mm)
deployed at 16-22 ATM after nominal balloon pre-dilatation. Expansion deficit (ED, %)
was the ratio of observed to predicted average stented diameter.
Results: DES were less expanded than predicted (ED  -10.5%, p0.001) but none
evidenced malapposition after high-pressure deployment. Mean ED was highest in
Endeavor vs. Xience or Resolute (-11.8% vs. -6.0% vs. -10.6%, p0.001, Fig 1). 98.4%
of Resolute frames were under-expanded vs. 93.7% Endeavor frames and 80.4% Xience
(p .001). ED was greater in ACS vs. non-ACS (-11.2% vs. -10.2%, p.002) and LAD
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AM www.jacc.tctabstracts2012.com
B86 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Imaging
P
O
ST
E
R
S
